TY - STD TI - Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5. ID - ref1 ER - TY - JOUR AU - Furer, V. AU - Rondaan, C. AU - Heijstek, M. W. PY - 2020 DA - 2020// TI - 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases JO - Ann Rheum Dis VL - 79 UR - https://doi.org/10.1136/annrheumdis-2019-215882 DO - 10.1136/annrheumdis-2019-215882 ID - Furer2020 ER - TY - JOUR AU - Westra, J. AU - Rondaan, C. AU - Assen, S. AU - Bijl, M. PY - 2015 DA - 2015// TI - Vaccination of patients with autoimmune inflammatory rheumatic diseases JO - Nat Rev Rheumatol VL - 11 UR - https://doi.org/10.1038/nrrheum.2014.206 DO - 10.1038/nrrheum.2014.206 ID - Westra2015 ER - TY - JOUR AU - Heijstek, M. W. AU - Bruin, L. M. O. AU - Bijl, M. AU - Borrow, R. AU - Klis, F. AU - Koné-Paut, I. AU - Fasth, A. AU - Minden, K. AU - Ravelli, A. AU - Abinun, M. AU - Pileggi, G. S. AU - Borte, M. AU - Wulffraat, N. M. PY - 2011 DA - 2011// TI - EULAR recommendations for vaccination in paediatric patients with rheumatic diseases JO - Ann Rheum Dis VL - 70 UR - https://doi.org/10.1136/ard.2011.150193 DO - 10.1136/ard.2011.150193 ID - Heijstek2011 ER - TY - JOUR AU - Groot, N. AU - Heijstek, M. W. AU - Wulffraat, N. M. PY - 2015 DA - 2015// TI - Vaccinations in paediatric rheumatology: an update on current developments JO - Curr Rheumatol Rep VL - 17 UR - https://doi.org/10.1007/s11926-015-0519-y DO - 10.1007/s11926-015-0519-y ID - Groot2015 ER - TY - JOUR AU - Silva, C. A. AU - Aikawa, N. E. AU - Bonfa, E. PY - 2013 DA - 2013// TI - Vaccinations in juvenile chronic inflammatory diseases: an update JO - Nat Rev Rheumatol VL - 9 UR - https://doi.org/10.1038/nrrheum.2013.95 DO - 10.1038/nrrheum.2013.95 ID - Silva2013 ER - TY - JOUR AU - Dell’Era, L. AU - Esposito, S. AU - Corona, F. AU - Principi, N. PY - 2011 DA - 2011// TI - Vaccination of children and adolescents with rheumatic diseases JO - Rheumatology (Oxford) VL - 50 UR - https://doi.org/10.1093/rheumatology/ker102 DO - 10.1093/rheumatology/ker102 ID - Dell’Era2011 ER - TY - JOUR AU - Pellegrino, P. AU - Radice, S. AU - Clementi, E. PY - 2015 DA - 2015// TI - Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: a systematic review JO - Vaccine. VL - 33 UR - https://doi.org/10.1016/j.vaccine.2015.05.041 DO - 10.1016/j.vaccine.2015.05.041 ID - Pellegrino2015 ER - TY - JOUR AU - Grein PY - 2016 DA - 2016// TI - HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know JO - Pediatr Rheumatol VL - 14 UR - https://doi.org/10.1186/s12969-016-0072-x DO - 10.1186/s12969-016-0072-x ID - Grein2016 ER - TY - JOUR AU - Lube, G. PY - 2014 DA - 2014// TI - Condyloma acuminatum by human papilloma virus infection in childhood-systemic lupus erythematosus patients JO - Acta Reumatol Port VL - 39 ID - Lube2014 ER - TY - JOUR AU - Lyrio, L. D. PY - 2013 DA - 2013// TI - Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus JO - Rheumatol Int VL - 33 UR - https://doi.org/10.1007/s00296-012-2426-0 DO - 10.1007/s00296-012-2426-0 ID - Lyrio2013 ER - TY - JOUR AU - Santana, I. U. PY - 2011 DA - 2011// TI - Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review JO - Clin Rheumatol VL - 30 UR - https://doi.org/10.1007/s10067-010-1606-0 DO - 10.1007/s10067-010-1606-0 ID - Santana2011 ER - TY - JOUR AU - Liu, H. PY - 2011 DA - 2011// TI - Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia JO - Rheumatology (Oxford) VL - 50 UR - https://doi.org/10.1093/rheumatology/keq304 DO - 10.1093/rheumatology/keq304 ID - Liu2011 ER - TY - JOUR AU - Ren, Z. AU - Laumann, A. E. AU - Silverberg, J. I. PY - 2019 DA - 2019// TI - Association of dermatomyositis with systemic and opportunistic infections in the United States JO - Arch Dermatol Res VL - 311 UR - https://doi.org/10.1007/s00403-019-01913-0)10.1007/s00403-019-01913-0) DO - 10.1007/s00403-019-01913-0)10.1007/s00403-019-01913-0) ID - Ren2019 ER - TY - JOUR AU - Lawson, E. F. PY - 2015 DA - 2015// TI - Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemiclupus erythematosus JO - Semin Arthritis Rheum VL - 44 UR - https://doi.org/10.1016/j.semarthrit.2015.01.002 DO - 10.1016/j.semarthrit.2015.01.002 ID - Lawson2015 ER - TY - JOUR AU - Hua, C. PY - 2015 DA - 2015// TI - Reasons for non-vaccination in French rheumatoid arthritis andspondyloarthritis patients JO - Rheumatology VL - 54 UR - https://doi.org/10.1093/rheumatology/keu531 DO - 10.1093/rheumatology/keu531 ID - Hua2015 ER - TY - JOUR AU - Morin, M. P. AU - Quach, C. AU - Fortin, E. AU - Chédeville, G. PY - 2012 DA - 2012// TI - Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre JO - Rheumatology (Oxford) VL - 51 UR - https://doi.org/10.1093/rheumatology/kes175 DO - 10.1093/rheumatology/kes175 ID - Morin2012 ER - TY - STD TI - BizjakM et al. Vaccination coverage in children with rheumatic diseases. Clin Exp Rheumatol 2020; 38: 164–170. ID - ref18 ER - TY - JOUR AU - Drolet, M. PY - 2015 DA - 2015// TI - Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(14)71073-4 DO - 10.1016/S1473-3099(14)71073-4 ID - Drolet2015 ER - TY - JOUR AU - Dillner, J. AU - Kjaer, S. K. AU - Wheeler, C. M. AU - Sigurdsson, K. AU - Iversen, O. E. PY - 2010 DA - 2010// TI - Four-year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial JO - BMJ. VL - 341 UR - https://doi.org/10.1136/bmj.c3493 DO - 10.1136/bmj.c3493 ID - Dillner2010 ER - TY - JOUR AU - Muñoz, N. PY - 2010 DA - 2010// TI - Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women JO - J Natl Cancer Inst VL - 102 UR - https://doi.org/10.1093/jnci/djp534 DO - 10.1093/jnci/djp534 ID - Muñoz2010 ER - TY - JOUR AU - Vichnin, M. PY - 2015 DA - 2015// TI - An overview of quadrivalent human papillomavirus vaccine safety JO - Pediatr Infect Dis J VL - 34 UR - https://doi.org/10.1097/INF.0000000000000793 DO - 10.1097/INF.0000000000000793 ID - Vichnin2015 ER - TY - JOUR AU - Geier, D. A. AU - Geier, M. R. PY - 2015 DA - 2015// TI - A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events JO - Clin Rheumatol VL - 34 UR - https://doi.org/10.1007/s10067-014-2846-1 DO - 10.1007/s10067-014-2846-1 ID - Geier2015 ER - TY - JOUR AU - Soldevilla, H. F. AU - Briones, S. F. R. AU - Navarra, S. V. PY - 2012 DA - 2012// TI - Systemic lupus erythematosus following HPV immunization or infection? JO - Lupus VL - 21 UR - https://doi.org/10.1177/0961203311429556 DO - 10.1177/0961203311429556 ID - Soldevilla2012 ER - TY - JOUR AU - Nicol, A. F. AU - Andrade, C. V. AU - Russomano, F. B. AU - Rodrigues, L. L. S. AU - Oliveira, N. S. AU - Provance, D. W. PY - 2016 DA - 2016// TI - HPV vaccines: a controversial issue? JO - Braz J Med Biol Res VL - 49 UR - https://doi.org/10.1590/1414-431x20155060 DO - 10.1590/1414-431x20155060 ID - Nicol2016 ER - TY - JOUR AU - Arnheim-Dahlström, L. PY - 2013 DA - 2013// TI - Autoimmune, neurological, and venous thromboembolic adverse events after immunization of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study JO - BMJ VL - 347 UR - https://doi.org/10.1136/bmj.f5906 DO - 10.1136/bmj.f5906 ID - Arnheim-Dahlström2013 ER - TY - JOUR AU - Chao, C. PY - 2012 DA - 2012// TI - Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine JO - J Intern Med VL - 271 UR - https://doi.org/10.1111/j.1365-2796.2011.02467.x DO - 10.1111/j.1365-2796.2011.02467.x ID - Chao2012 ER - TY - JOUR PY - 2017 DA - 2017// TI - Human papillomavirus vaccines: WHO position paper, May 2017 JO - Wkly Epidemiol Rec VL - 19 ID - ref28 ER - TY - JOUR AU - Genovese, C. AU - Fauci, V. AU - Squeri, A. AU - Trimarchi, G. AU - Squeri, R. PY - 2018 DA - 2018// TI - HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature JO - J Prev Med Hyg VL - 59 UR - https://doi.org/10.15167/2421-4248/jpmh2018.59.3.998 DO - 10.15167/2421-4248/jpmh2018.59.3.998 ID - Genovese2018 ER - TY - JOUR AU - Gronlund, O. PY - 2016 DA - 2016// TI - Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study JO - J Intern Med VL - 280 UR - https://doi.org/10.1111/joim.12535 DO - 10.1111/joim.12535 ID - Gronlund2016 ER - TY - STD TI - Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis, Coordenação-geral do Programa Nacional de Imunizações. Informe técnico da ampliação da oferta das vacinas papilomavírus humano 6, 11, 16 e 18 (recombinante) – vacina HPV quadrivalente e meningocócica C (conjugada). Brasilia, 2018. ID - ref31 ER - TY - STD TI - World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization April 2014 – Conclusions and Recommendations. Wkly Epidemiol Rec. 2014;21(89):221–236. ID - ref32 ER - TY - JOUR AU - Heijstek, M. W. AU - Scherpenisse, M. AU - Groot, N. AU - Tacke, C. AU - Schepp, R. M. AU - Buisman, A. M. PY - 2014 DA - 2014// TI - Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-203429 DO - 10.1136/annrheumdis-2013-203429 ID - Heijstek2014 ER - TY - JOUR AU - Heijstek, M. W. AU - Scherpenisse, M. AU - Groot, N. AU - Wulffraat, N. M. AU - Klis, F. R. PY - 2013 DA - 2013// TI - Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis JO - J Rheumatol VL - 40 UR - https://doi.org/10.3899/jrheum.130246 DO - 10.3899/jrheum.130246 ID - Heijstek2013 ER - TY - JOUR AU - Bohan, A. AU - Peter, J. B. PY - 1975 DA - 1975// TI - Polymyositis and Dermatomyositis JO - N Engl J Med VL - 292 UR - https://doi.org/10.1056/NEJM197502132920706 DO - 10.1056/NEJM197502132920706 ID - Bohan1975 ER - TY - STD TI - Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization Regional Office for the Western Pacific Region. World Health Organization. Manila: WHO Press; 2013. ID - ref36 ER - TY - JOUR AU - Lovell, D. J. PY - 1999 DA - 1999// TI - Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS) JO - Arthritis Rheum VL - 42 UR - https://doi.org/3.0.CO;2-8 DO - 3.0.CO;2-8 ID - Lovell1999 ER - TY - JOUR AU - Rider, L. G. PY - 2011 DA - 2011// TI - Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment JO - Arthritis Care Res VL - 63 UR - https://doi.org/10.1002/acr.20532 DO - 10.1002/acr.20532 ID - Rider2011 ER - TY - JOUR AU - Lazarevic, D. PY - 2013 DA - 2013// TI - The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis JO - Ann Rheum Dis VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-201483 DO - 10.1136/annrheumdis-2012-201483 ID - Lazarevic2013 ER - TY - JOUR AU - Rider, L. G. PY - 2018 DA - 2018// TI - Update on outcome assessment in myositis JO - Nat Rev Rheumatol VL - 14 UR - https://doi.org/10.1038/nrrheum.2018.33 DO - 10.1038/nrrheum.2018.33 ID - Rider2018 ER - TY - JOUR AU - Ruperto, N. PY - 2010 DA - 2010// TI - (PRINTO and PRCSG). The paediatric rheumatology international trials organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis JO - Arthritis Care Res VL - 62 UR - https://doi.org/10.1002/acr.20280 DO - 10.1002/acr.20280 ID - Ruperto2010 ER - TY - JOUR AU - Mok, C. C. AU - Ho, L. Y. AU - Fong, L. S. AU - To, C. H. PY - 2013 DA - 2013// TI - Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study JO - Ann Rheum Dis VL - 72 UR - https://doi.org/10.1136/annrheumdis-2012-201393 DO - 10.1136/annrheumdis-2012-201393 ID - Mok2013 ER - TY - JOUR AU - Soybilgic, A. AU - Onel, K. B. AU - Utset, T. AU - Alexander, K. AU - Wagner-Weiner, L. PY - 2013 DA - 2013// TI - Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years JO - Pediatr Rheumatol Online J VL - 11 UR - https://doi.org/10.1186/1546-0096-11-29 DO - 10.1186/1546-0096-11-29 ID - Soybilgic2013 ER - TY - JOUR AU - Dhar, J. P. AU - Essenmacher, L. AU - Dhar, R. AU - Magee, A. AU - Ager, J. AU - Sokol, R. J. PY - 2017 DA - 2017// TI - The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus JO - Vaccine. VL - 35 UR - https://doi.org/10.1016/j.vaccine.2017.04.001 DO - 10.1016/j.vaccine.2017.04.001 ID - Dhar2017 ER - TY - STD TI - Grein, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multicentre study. LUPUS. 2020. https://doi.org/10.1177/0961203320928406. ID - ref45 ER - TY - JOUR AU - Mok, C. C. AU - Ho, L. Y. AU - To, C. H. PY - 2018 DA - 2018// TI - Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus JO - Vaccine VL - 36 UR - https://doi.org/10.1016/j.vaccine.2018.04.056 DO - 10.1016/j.vaccine.2018.04.056 ID - Mok2018 ER -